Pharmsynthez (MOEX:LIFE)

Pharmsynthez Statistics

Total Valuation

Pharmsynthez has a market cap or net worth of RUB 1.36 billion. The enterprise value is 2.05 billion.

Market Cap	1.36B
Enterprise Value	2.05B

Important Dates

The last earnings date was Tuesday, June 2, 2026.

Earnings Date	Jun 2, 2026
Ex-Dividend Date	n/a

Share Statistics

Pharmsynthez has 301.01 million shares outstanding.

Current Share Class	301.01M
Shares Outstanding	301.01M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.81
PB Ratio	0.76
P/TBV Ratio	0.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-9.50
EV / Sales	13.31
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.29, with a Debt / Equity ratio of 0.22.

Current Ratio	0.29
Quick Ratio	0.21
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-7.00

Financial Efficiency

Return on equity (ROE) is -11.45% and return on invested capital (ROIC) is -5.33%.

Return on Equity (ROE)	-11.45%
Return on Assets (ROA)	-4.34%
Return on Invested Capital (ROIC)	-5.33%
Return on Capital Employed (ROCE)	-10.86%
Weighted Average Cost of Capital (WACC)	5.14%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.06
Inventory Turnover	1.65

Taxes

In the past 12 months, Pharmsynthez has paid 28.71 million in taxes.

Income Tax	28.71M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.60% in the last 52 weeks. The beta is 0.14, so Pharmsynthez's price volatility has been lower than the market average.

Beta (5Y)	0.14
52-Week Price Change	-24.60%
50-Day Moving Average	3.92
200-Day Moving Average	5.11
Relative Strength Index (RSI)	63.97
Average Volume (20 Days)	9,839,310

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharmsynthez had revenue of RUB 154.00 million and -215.70 million in losses.

Revenue	154.00M
Gross Profit	36.54M
Operating Income	-193.08M
Pretax Income	-186.99M
Net Income	-215.70M
EBITDA	n/a
EBIT	-193.08M
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 4.76 million in cash and 386.19 million in debt, with a net cash position of -381.43 million or -1.27 per share.

Cash & Cash Equivalents	4.76M
Total Debt	386.19M
Net Cash	-381.43M
Net Cash Per Share	-1.27
Equity (Book Value)	1.78B
Book Value Per Share	n/a
Working Capital	-684.16M

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 23.73%, with operating and profit margins of -125.38% and -140.07%.

Gross Margin	23.73%
Operating Margin	-125.38%
Pretax Margin	-121.42%
Profit Margin	-140.07%
EBITDA Margin	n/a
EBIT Margin	-125.38%
FCF Margin	n/a

Dividends & Yields

Pharmsynthez does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-15.91%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1